Nu-Med Plus (NUMD) EBIT Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) EBIT Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.67 Bn | 176.38 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 128.91 Bn | 126.03 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 108.84 Bn | 99.62 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 48.68 Bn | 45.01 Bn | 1.29 Bn | 7.13% |
| 6 | Dexcom | 28.42 Bn | 27.31 Bn | 750.30 Mn | 75.54% |
| 7 | GE HealthCare Technologies | 28.38 Bn | 26.09 Bn | 1.98 Bn | -2.70% |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.50 Bn | 22.38 Bn | 2.07 Bn | 34.83% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -15.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.14% |
| Sep 30, 2025 | 44.22% |
| Jun 30, 2025 | 43.60% |
| Mar 31, 2025 | 32.07% |
| Dec 31, 2024 | 56.43% |
| Sep 30, 2024 | 47.21% |
| Jun 30, 2024 | 60.07% |
| Mar 31, 2024 | 61.36% |
| Dec 31, 2023 | 52.16% |
| Sep 30, 2023 | 67.71% |
| Jun 30, 2023 | 70.56% |
| Mar 31, 2023 | 43.97% |
| Dec 31, 2022 | 69.40% |
| Sep 30, 2022 | 26.50% |
| Jun 30, 2022 | 38.01% |
| Mar 31, 2022 | 47.98% |
| Dec 31, 2021 | 30.59% |
| Sep 30, 2021 | 39.02% |
| Jun 30, 2021 | -14.31% |
| Mar 31, 2021 | -35.76% |